| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 0.0 | 0.1 | 0.1 |
| Total income | 0.0 | 0.1 | 0.1 |
| Profit before exceptional items & tax | -0.1 | 0.1 | -0.0 |
| Profit before tax | -0.1 | 0.1 | -0.0 |
| Net profit | -0.1 | 0.1 | -0.0 |
| Operating margin | 0.0% | 100.0% | 0.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
BSE results filing, NSE: AMARDEE. Figures extracted from the filing.
Amerise Biosciences Ltd: key numbers
- Share price
- ₹0.82
- Market cap
- ₹5.42 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹0.02 Cr
- P/E (TTM)
- -102.6×Sector 28.6×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Amerise Biosciences Ltd
All →Amerise Biosciences Annual General Meeting
Amerise Biosciences Limited conducted its 41st Annual General Meeting on September 24, 2026. Shareholders approved financial statements and the appointment of a new Wholetime Director and CFO.
Amerise Biosciences Annual Report
Amerise Biosciences has submitted its Annual Report for the financial year 2024-25. The company scheduled its 41st Annual General Meeting for September 24, 2026.
Amerise Biosciences Annual General Meeting
Amerise Biosciences Ltd has submitted the notice for its 41st Annual General Meeting, scheduled to be held on September 24, 2026.
Amerise Biosciences Capital Structure Change
Snehjeev Ventures Private Limited and PACs acquired 76,725 equity shares of Amerise Biosciences Ltd. The acquisition increases their aggregate stake from 10.92% to 11.04%.
Amerise Biosciences Management Change
Amerise Biosciences Limited has appointed Ms. Soni Pandiya as the new Company Secretary, replacing Ms. Minal Lakhani who resigned for better career opportunities.
Amerise Biosciences Capital Structure Change
Snehjeev Ventures Pvt. Ltd. and PACs increased their stake in Amerise Biosciences Ltd by 0.04% through an open market purchase, reaching 9.02% total holding.